ann out re immunoxel, page-2

IMMEDIATE RELEASE - 30 May 2011
Collaboration Agreement to Accelerate
ImmunoXel Introduction for TB Treatment
? Agreement to Fast-Track New ImmunoXel Tablet Formulation
Healthcare group, Stirling Products Limited (ASX:STI) advises that the Company (Stirling)
and its joint venture partner, Zodiac Capital Limited (Zodiac), have entered into a conditional
agreement with Canadian based Immune Network Limited with regard to the Stirling
exclusively licensed ImmunoXel product together with an improved formulation of
ImmunoXel developed through recent work by Immune Network.
The new sublingual ImmunoXel tablet formulation has already demonstrated improved
effectiveness and potential for accelerated cure rate. Importantly, the decreased cost of
production, improved stability and ease of use of the new ImmunoXel formulation is likely to
improve the accessibility and availability of the product for TB patients.
ImmunoXel (Dzherelo) is a multi-herbal extract that has been demonstrated in numerous
clinical trials to be extraordinarily effective where provided as an adjunct in all forms of TB
treatment, including the drug resistant forms MDR-TB and XDR-TB, as well as for patients
with HIV/TB co-infection.
Under the terms of the Agreement, Stirling and Immune Network will continue with their
respective research and development work. Stirling, following meeting at the National
Institutes of Health (NIH) in Washington, USA, will continue with its plans for a Cooperative
Research Agreement with the NIH, to further establish the effect of ImmunoXel on
HIV-related endpoints and Immune Network will produce batches of the new ImmunoXel
tablet formulation and continue clinical demonstration trials of the new product.
The Agreement is conditional upon Immune Network becoming current in its statutory
filings, following which Immune Network will issue to Stirling 20 million shares for the nonexclusive
marketing rights to ImmunoXel and providing Stirling with direct exposure to
potential profitability from Immune Network's other TB immunotherapy, V-5 Immunitor.
Further Stirling will subscribe to 5 million Immune shares at US$0.02 per share with such
subscription to be satisfied by the issue of 12.5 million Stirling shares and 333,333 Zodiac
shares. The Agreement also resolves the differences recently reported following the
development of the new sublingual tablet form of ImmunoXel by Immune Network Limited.